Sébastien Anguille

5.1k citations

88 papers · 2.7k indexed · 1 hit paper · h-index 29

Immunology top 1%
- Immunotherapy and Immune Responses 35
- Immune Cell Function and Interaction 23
- T-cell and B-cell Immunology 11
Oncology top 2%
- CAR-T cell therapy research 45
Hematology top 2%
- Multiple Myeloma Research and Treatments 10
Molecular Biology top 10%
- RNA Interference and Gene Delivery 9
- Viral Infectious Diseases and Gene Expression in Insects 8
Virology top 10%
Genetics
- Virus-based gene therapy research 9

Co-authors: Viggo Van Tendeloo Zwi Berneman Evelien Smits Eva Lion Heleen H. Van Acker Yannick Willemen Gils Roex Diana Campillo-Davó
Cited by: Immunology Oncology Hematology
Journals: Journal of Clinical Oncology (7 papers)SHILAP Revista de lepidopterología (2 papers)Blood (13 papers)
Partner nations: Belgium Netherlands United States

In The Last Decade

Sébastien Anguille

82 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Sébastien Anguille

Since Specialization

Citations

This map shows the geographic impact of Sébastien Anguille's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sébastien Anguille with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sébastien Anguille more than expected).

Fields of papers citing papers by Sébastien Anguille

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sébastien Anguille. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sébastien Anguille. The network helps show where Sébastien Anguille may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Sébastien Anguille, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Sébastien Anguille Line = papers co-authored together Sébastien Anguille links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Downregulation of MICA/MICB improves cell persistence and clinical activity of NKG2DL CAR T-cells in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic neoplasia Leukemia ·Daniel A. Pollyea,Tessa Kerre,Dries Deeren,Y Beguin,Tara L. Lin,David A. Sallman,Sébastien Anguille,William Blum,Anne Flament,Eytan Breman,Caroline Lonez	2025	1
2	Atalanta-1: A Phase 1/2 Trial of GLPG5101, a Fresh, Stem-like, Early Memory CD19 CAR T-Cell Therapy with a 7-Day Vein-to-Vein Time, for the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma Blood ·Marie José Kersten,Kirsten Saevels,Évelyne Willems,Marte C. Liefaard,Stavros Milatos,Margot J. Pont,Claire Vennin,Eva Santermans,Anna D.D. van Muyden,Jeevan K. Shetty,Esmée P. Hoefsmit,Omotayo Fasan,Maria T. Kuipers,Sébastien Anguille,Joost S.P. Vermaat	2024	1
3	Real‐life data of luspatercept in lower‐risk myelodysplastic syndromes advocate new research objectives SHILAP Revista de lepidopterología ·Bert Heyrman,Stef Meers,Sélim Sid,Natalie Put,Koen Theunissen,Koen Van Eygen,Nathan De Beule,Maxime Clauwaert,Helena Maes,Alexander Salembier,Jan Lemmens,Ann Van de Velde,Dominik Selleslag,Jason Bouziotis,Ann De Becker,Sébastien Anguille	2024	0
4	Integration of the PD-L1 inhibitor atezolizumab and WT1/DC vaccination into standard-of-care first-line treatment for patients with epithelioid malignant pleural mesothelioma—Protocol of the Immuno-MESODEC study PLoS ONE ·Jolien Van den Bossche,Maxime De Laere,Koen Deschepper,Paul Germonpré,Y. Valcke,Jan Lamont,Barbara Stein,Kirsten Van Camp,Charlotte Germonpré,Griet Nijs,Ella Roelant,Sébastien Anguille,Eva Lion,Zwi Berneman	2024	4
5	In vitro expansion of Wilms’ tumor protein 1 epitope-specific primary T cells from healthy human peripheral blood mononuclear cells STAR Protocols ·Sanne van der Heijden,Donovan Flumens,Maarten Versteven,Stefanie Peeters,Hans De Reu,Diana Campillo-Davó,Yannick Willemen,Benson Ogunjimi,Viggo Van Tendeloo,Zwi Berneman,Sébastien Anguille,Evelien Smits,Eva Lion	2023	2
6	Rationale for and Design of Papilio-1: A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Feasibility, Safety, and Efficacy of Point-of-Care-Manufactured Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells (GLPG5301) in Relapsed/Refractory Multiple Myeloma Blood ·Niels W.C.J. van de Donk,Sébastien Anguille,Jo Caers,Marte C. Liefaard,Christian Jacques,Anna D.D. van Muyden	2023	1
7	One-step CRISPR-Cas9-mediated knockout of native TCRαβ genes in human T cells using RNA electroporation STAR Protocols ·Donovan Flumens,Diana Campillo-Davó,Ibo Janssens,Gils Roex,Jorrit De Waele,Sébastien Anguille,Eva Lion	2023	1
8	Combined Results of Two Cross-Sectional Surveys on the Participation in Clinical Trials and the e-Consent Procedure in the Landscape of Haematology SHILAP Revista de lepidopterología ·Bert Heyrman,Stef Meers,Ann Van de Velde,Sébastien Anguille	2023	0
9	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma Journal of Hematology & Oncology ·Gils Roex,Marijke Timmers,Kristien Wouters,Diana Campillo-Davó,Donovan Flumens,Wilfried Schroyens,Yiwei Chu,Zwi Berneman,Eva Lion,Feifei Luo,Sébastien Anguille	2020	123
10	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15 Cancers ·Heleen H. Van Acker,Zoë P. Van Acker,Maarten Versteven,Peter Ponsaerts,Daniela Pende,Zwi Berneman,Sébastien Anguille,Viggo Van Tendeloo,Evelien Smits	2019	8
11	Bisphosphonates for cancer treatment: Mechanisms of action and lessons from clinical trials Pharmacology & Therapeutics ·Heleen H. Van Acker,Sébastien Anguille,Yannick Willemen,Evelien Smits,Viggo Van Tendeloo	2015	167
12	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy Pharmacological Reviews ·Sébastien Anguille,Evelien Smits,Christian Bryant,Heleen H. Van Acker,Herman Goossens,Eva Lion,Phillip D. Fromm,Derek N.J. Hart,Viggo Van Tendeloo,Zwi Berneman	2015	122
13	Empowering gamma delta T cells with antitumor immunity by dendritic cell-based immunotherapy OncoImmunology ·Heleen H. Van Acker,Sébastien Anguille,Viggo Van Tendeloo,Eva Lion	2015	52
14	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA–Transfected Dendritic Cells Transplantation ·Amaryllis H. Van Craenenbroeck,Evelien Smits,Sébastien Anguille,Ann Van de Velde,Barbara Stein,Tessa Braeckman,Kirsten Van Camp,Griet Nijs,Margareta Ieven,Herman Goossens,Zwi Berneman,Viggo Van Tendeloo,Gert A. Verpooten,Pierre Van Damme,Nathalie Cools	2014	25
15	Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo Molecular Therapy — Nucleic Acids ·Daphné Benteyn,Sébastien Anguille,Sandra Van Lint,Carlo Heirman,An M. T. Van Nuffel,Jurgen Corthals,Sebastian Ochsenreither,Wim Waelput,Katrien Van Beneden,Karine Breckpot,Viggo Van Tendeloo,Kris Thielemans,Aude Bonehill	2013	40
16	Vaccination thérapeutique à base de cellules dendritiques contre la leucémie aiguë myéloïde Bulletin du Cancer ·Sébastien Anguille,Viggo Van Tendeloo,Zwi Berneman	2012	4
17	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential PLoS ONE ·Sébastien Anguille,Eva Lion,Jurjen Tel,I. Jolanda M. de Vries,Karen Couderé,Phillip D. Fromm,Viggo Van Tendeloo,Evelien Smits,Zwi Berneman	2012	47
18	Interferon-α in acute myeloid leukemia: an old drug revisited Leukemia ·Sébastien Anguille,Eva Lion,Yannick Willemen,Viggo Van Tendeloo,Zwi Berneman,Evelien Smits	2011	88
19	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers Human Vaccines ·Sébastien Anguille,Eva Lion,Evelien Smits,Zwi Berneman,Viggo Van Tendeloo	2011	26
20	An unusual presentation of gallstone disease QJM ·Sébastien Anguille	2010	1

About Sébastien Anguille

Sébastien Anguille is a scholar working on Immunology, Oncology and Hematology, having authored 88 papers that have together received 2.7k indexed citations. Recurring topics across this work include CAR-T cell therapy research (45 papers), Immunotherapy and Immune Responses (35 papers), Immune Cell Function and Interaction (23 papers), T-cell and B-cell Immunology (11 papers), Multiple Myeloma Research and Treatments (10 papers), Virus-based gene therapy research (9 papers), RNA Interference and Gene Delivery (9 papers) and Viral Infectious Diseases and Gene Expression in Insects (8 papers). The work is most often cited by research in Immunology (1.7k citations), Oncology (1.5k citations) and Hematology (426 citations). Sébastien Anguille has collaborated with scholars based in Belgium, Netherlands and United States. Frequent co-authors include Viggo Van Tendeloo, Zwi Berneman, Evelien Smits, Eva Lion, Heleen H. Van Acker, Yannick Willemen, Gils Roex, Diana Campillo-Davó, Herman Goossens and Jurjen Tel. Their work appears in journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact